roovestor

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Bayer AG | Europe | Pharma | Fiscal Year 2020 | ISIN: DE000BAY0017
Reading Time: 8 minutes
Bayer, the inventor of Aspirin® – one of the world’s most prominent drugs – reported its annual results for 2020. The pandemic and the seemingly never ending story around the Monsanto lawsuit are casting long shadows on the former German pharmaceutical flagship company. Bayer share prices are down by about -50 % compared to their all-time high in 2017. Find out below how the company performed in 2020, which was without a doubt one of the most challenging years since its inception.

Werbung / Advertisement

Qualitative Analysis

Sorry, this part of the article is for roovestor PREMIUM users only.

Login or sign up here to get your roovestor PREMIUM account with unlimited access to all articles

Quantitative Analysis

Bayer FY 2020 – roovestor company score

Unlock access with roovestor PREMIUM.
Login or Sign Up here!

Unlock access with roovestor PREMIUM.
Login or Sign Up here!

Unlock access with roovestor PREMIUM.
Login or Sign Up here!

Unlock access with roovestor PREMIUM.
Login or Sign Up here!

Unlock access with roovestor PREMIUM.
Login or Sign Up here!

Unlock access with roovestor PREMIUM.
Login or Sign Up here!

Disclaimer

We assume no liability for the accuracy of the financial data. Sources of the financial data are foremost IR websites of the company subject to the analysis. Additionally we rely on further data and information from Thomson Reuters EIKON. Moreover, unless better data is available, we do our own calculations of available data for KPI determination. Our stock analyses are by no means to be understood as a buy or sell recommendation and do not provide any conclusions regarding the future development of the company (and thus the future price development of the share).